Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Børset

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Annals of Hematology|March 21, 2002
Syndecan-1 in B lymphoid malignanciesR D Sanderson, M Børset
Annales Chirurgiae Et Gynaecologiae|January 1, 1995
Mobility, survival and nursing-home requirements after hip fractureV Finsen, M Børset, I Rossvoll
Acta Diabetologica|September 25, 1998
Elevated hepatocyte growth factor in sera from patients with insulin-dependent diabetes mellitusB Kulseng, M Børset, T Espevik, et al.
Current Drug Targets|September 24, 2005
Identification of new targets for therapy of osteolytic bone disease in multiple myelomaØ Hjertner, T Standal, M Børset, et al.
Injury|January 1, 1992
Preoperative traction in patients with hip fracturesV Finsen, M Børset, G E Buvik, et al.
Leukemia & Lymphoma|February 26, 1999
The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignanciesM Børset, C Seidel, H Hjorth-Hansen, et al.
Medical Oncology (Northwood, London, England)|November 20, 1998
Role of hepatocyte growth factor and its receptor c-met in multiple myelomaC Seidel, M Børset, H Hjorth-Hansen, et al.
Blood|September 26, 2000
Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteinsM Børset, O Hjertner, S Yaccoby, et al.
Leukemia & Lymphoma|April 7, 2000
Matrix metalloproteinases in multiple myelomaT Kelly, M Børset, E Abe, et al.
Blood|February 3, 1998
Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study GroupC Seidel, M Børset, I Turesson, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Annals of Hematology|March 21, 2002
Syndecan-1 in B lymphoid malignanciesR D Sanderson, M Børset
Annales Chirurgiae Et Gynaecologiae|January 1, 1995
Mobility, survival and nursing-home requirements after hip fractureV Finsen, M Børset, I Rossvoll
Acta Diabetologica|September 25, 1998
Elevated hepatocyte growth factor in sera from patients with insulin-dependent diabetes mellitusB Kulseng, M Børset, T Espevik, et al.
Current Drug Targets|September 24, 2005
Identification of new targets for therapy of osteolytic bone disease in multiple myelomaØ Hjertner, T Standal, M Børset, et al.
Injury|January 1, 1992
Preoperative traction in patients with hip fracturesV Finsen, M Børset, G E Buvik, et al.
Leukemia & Lymphoma|February 26, 1999
The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignanciesM Børset, C Seidel, H Hjorth-Hansen, et al.
Medical Oncology (Northwood, London, England)|November 20, 1998
Role of hepatocyte growth factor and its receptor c-met in multiple myelomaC Seidel, M Børset, H Hjorth-Hansen, et al.
Blood|September 26, 2000
Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteinsM Børset, O Hjertner, S Yaccoby, et al.
Leukemia & Lymphoma|April 7, 2000
Matrix metalloproteinases in multiple myelomaT Kelly, M Børset, E Abe, et al.
Blood|February 3, 1998
Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study GroupC Seidel, M Børset, I Turesson, et al.
Pageof 2